ARCH — Arch Biopartners Share News
0.000.00%
Last trade - 00:00- CA$57.06m
- CA$59.79m
- CA$0.28m
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide
Brief: Arch Biopartners To Settle $2.6 Million In Deferred Convertible Notes
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Gmp Manufacturing Of Cilastatin Drug Product
Brief: Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Brief: Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as Treatment to Prevent Acute Kidney Injury
Brief: Arch Biopartners Receives Health Canada Approval To Conduct Phase II Trial For LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Brief: Arch Biopartners Receives Approval From Ethics Committee In Turkey To Proceed With Phase Ii Cardiac Surgery
Brief: Arch Biopartners Submits Application To Turkey To Conduct Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial For LSALT Peptide
Brief: Arch Biopartners Receives Permission From US FDA To Proceed With Phase II Acute Kidney Injury Trial
Brief: Arch Biopartners Announces Positive Results Of Dose Escalation Human Trial For Lsalt Peptide
Brief: Arch Biopartners Receives Funding For Development Of LSALT Peptide Drug Program
Brief: Arch Biopartners - Health Canada Has Approved Amendment To CATCO Protocol To Include Lsalt Peptide In New Dosing Arm Of Trial
Brief: Arch Scientists Publish Data On The Mechanism Of Action And Efficacy Of Lead Drug Candidate Lsalt Peptide In The Prevention Of Acute Kidney Injury
Brief: Research Ethics Board approves amendment to Canadian Treatments for COVID-19 Trial to include LSALT Peptide
Brief: Arch Biopartners’ Lead Drug Lsalt Peptide To Enter The Canadian Treatments For Covid-19 (Catco) Trial